Overview
US biopharma firm's 2025 net loss narrowed as operating expenses declined year over year
Lower R&D and admin costs followed completion of key clinical trial phases
Company raised $28 mln in oversubscribed financing, extending cash runway into 2027
Outlook
Clene plans to file NDA for CNM-Au8 in ALS by end of June 2026
Company expects cash runway to end of Q3 2026, with financing extending into 2027
Clene expects FDA Type C meeting minutes early in Q2 2026
Result Drivers
LOWER R&D SPENDING - Decreased research and development expenses due to completion of blinded phases and open-label extensions of key ALS trials, and higher grant revenue related to NIH-EAP enrollment
LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell due to lower insurance, legal, investor relations, and personnel costs
LOWER INTEREST AND ONE-TIME EXPENSES - Other expense declined due to lower interest expense and absence of one-time losses from prior year
Company press release: ID:nGNX8jB7Tc
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income | -$26.17 mln | ||
FY Basic EPS | -$2.65 | ||
FY Income From Operations | -$23.08 mln | ||
FY Operating Expenses | $23.28 mln | ||
FY Pretax Profit | -$26.17 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Clene Inc is $30.00, about 437.6% above its March 11 closing price of $5.58
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments